Disentangling contributions of reproductive tract infections to hiv acquisition in african women

Sexually Transmitted Diseases

Volumn 36, Issue 6, 2009, Pages 357-364

  Van De Wijgert, Janneke H H M ^a,i   Morrison, Charles S ^a   Brown, Joelle ^b   Kwok, Cynthia ^c   Van Der Pol, Barbara ^b   Chipato, Tsungai ^d   Byamugisha, Josaphat K ^e   Obs, Dip ^f   Padian, Nancy ^g   Salata, Robert A ^h  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f MAKERERE UNIVERSITY   (Uganda)

^g RTI INTERNATIONAL   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ Center for Poverty Related Communicable Diseases   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZATHINE PENICILLIN; CIPROFLOXACIN; CLOTRIMAZOLE; DOXYCYCLINE; ERYTHROMYCIN; KANAMYCIN; MEDROXYPROGESTERONE ACETATE; METRONIDAZOLE; MICONAZOLE; NORFLOXACIN; NYSTATIN; ORAL CONTRACEPTIVE AGENT;

ADULT; AFRICA; ARTICLE; ATTRIBUTABLE RISK; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COHORT ANALYSIS; CONDOM; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY PLANNING; FEMALE; FEMALE GENITAL TRACT INFECTION; GONORRHEA; HERPES; HERPES SIMPLEX VIRUS 2; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MYCOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; PATIENT COUNSELING; POLYMERASE CHAIN REACTION; POPULATION RISK; PROSPECTIVE STUDY; RISK REDUCTION; SCREENING; SEXUALLY TRANSMITTED DISEASE; STRUCTURED QUESTIONNAIRE; SYPHILIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UGANDA; VAGINA FLORA; VAGINITIS; YEAST; ZIMBABWE;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; UGANDA; VAGINA; YOUNG ADULT; ZIMBABWE;

EID: 67049098800     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181a4f695     Document Type: Article

References (39)

1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Inf 1999; 75:3-17.
2. Freeman EE, Weiss HA, Glynn GR, et al. Herpes simplex type 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
3. McClelland RS, Sangaré L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquistion. J Infect Dis 2007; 195:6698-6702.
4. Brown JM, Wald A, Hubbard A, et al. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:1515-1523.
5. Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis is a risk factor for HIV acquisition in African women. J Infect Dis 2008; 197:548-554.
6. Myer L, Kuhn L, Stein ZA, et al. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5:786-794.
7. Kapiga SH, Lyamuya EF, Lwihula GK, et al. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12:75-84.
8. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquistion of HIV. AIDS 1998; 12:1699-1706.
9. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactoba-cilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-1868.
10. van de Wijgert J, Morrison C, Cornelisse P, et al. Bacterial vaginosis and vaginal yeasts, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immun Defic Syndr 2008, in press.
11. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391-1393.
12. Schwebke JR, Weiss HL. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transm Dis 2002; 29:59-64.
13. Morse SA, Ballard RC, Holmes KK, et al. Atlas of Sex ually Transm itted Dis ease and AIDS, 3rd ed. Mosby: 2002.
14. WHO/UNAIDS. Consultation on STI interventions for preventing HIV: appraisal of the evidence. Geneva, Switzerland: World Organization and Joint United Nations Programme on HIV/ AIDS; 2008.
15. Korenromp EL, de Vlas SJ, Nagelkerke NJ, et al. Estimating the magnitude of STD cofactor effects on HIV transmission. How well can it be done? Sex Transm Dis 2001; 28:613-621.
16. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346: 530-536.
17. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525-235.
18. Kamali A, Quigley M, Nakiyingi J, et al. Syndromic management of sexually transmitted infections and behavior change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 3003; 361:645-652.
19. Gregson S, Adamson S, Papaya S, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in Eastern Zimbabwe. PloS Med 2007; 4:e102.
20. Kaul R, Kimani J, Nagelkerke N, et al. Monthly antibiotic che-moprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers. A randomized controlled trial. JAMA 2004; 291:2555-2562.
21. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
22. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
23. Nagot N, Ouedraogo A, Defer M, et al. Association between bacterial vaginosis and herpes simplex virus type 2 infection: implications for HIV acquisition studies. Sex Transm Infect 2007; 83:365-368.
24. Kaul R, Nagelkerke N, Kimani J, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptability to multiple sexually transmitted infections. J Infect Dis 2007; 196:1692-1697.
25. UNAIDS. Report on the global AIDS epidemic, 2007. Geneva, Switzerland: UNAIDS; 2007.
26. Mahomva A, Greby S, Dube S, et al. HIV prevalence and trends from data in Zimbabwe, 1997-2004. Sex Transm Infect 2006; 82(suppl l):i42-47.
27. Morrison CS, Richardson BA, Mmiro F, et al. for the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.
28. Laeyendecker O, Henson C, Gray RH, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794-1796.
29. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
30. Sonis J. A closer look at confounding. Family Med 1998; 30:584-588.
31. Norris Turner A, Morrison CS, Padian NS, et al. Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda. AIDS 2007; 21:1779-1789.
32. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998; 88:15-19.
33. Rowe AK, Powell KE, Flanders D. Why population attributable fractions can sum to more than one. Am J Prev Med 2004; 26:243-249.
34. Orroth KK, White RG, Korenromp EL, et al. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis 2006; 33:536-544.
35. Gray RH, Wawer MJ, Sewankambo NK, et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. AIDS 1999; 13:2113-2123.
36. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 2004; 80:8-11.
37. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004; 11(suppl 3):161A-169A.
38. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PloS One 2008; 21:e2230.
39. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008; 197:1361-1368.